View Item 

Show simple item record

PD‐1 inhibition in congenital pigment synthesizing metastatic melanoma

dc.contributor.authorWeyand, Angela C.
dc.contributor.authorMody, Rajen J.
dc.contributor.authorRabah, Raja M.
dc.contributor.authorOpipari, Valerie P.
dc.date.accessioned2017-12-15T16:48:13Z
dc.date.available2019-03-01T21:00:17Zen
dc.date.issued2018-01
dc.identifier.citationWeyand, Angela C.; Mody, Rajen J.; Rabah, Raja M.; Opipari, Valerie P. (2018). "PD‐1 inhibition in congenital pigment synthesizing metastatic melanoma." Pediatric Blood & Cancer 65(1): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/139985
dc.description.abstractA newborn female child was born with a congenital pigment synthesizing melanoma of the scalp. Further workup revealed metastatic disease within the liver, lungs, and left tibia. Whole exome sequencing was performed on multiple samples that revealed one somatic mutation, lysine methyltransferase 2C (KMT2C), at low allelic frequency but no v‐Raf murine sarcoma viral oncogene homolog B (BRAF), NF‐1 mutation. Programmed death ligand 1 was moderately expressed. Treatment was initiated with the programmed cell death protein 1 inhibitor nivolumab. The patient tolerated this treatment well with minimal toxicity. She is now over a year out from initial diagnosis, continuing on nivolumab, with stable disease.
dc.publisherNIH Publication # 09‐7473
dc.publisherWiley Periodicals, Inc.
dc.subject.otherPD‐1 inhibition
dc.subject.otherpigment synthesizing
dc.subject.otherpediatric
dc.subject.othercongenital
dc.subject.othermetastatic melanoma
dc.titlePD‐1 inhibition in congenital pigment synthesizing metastatic melanoma
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139985/1/pbc26702.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139985/2/pbc26702_am.pdf
dc.identifier.doi10.1002/pbc.26702
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceMody RJ, Wu YM, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015; 314 ( 9 ): 913 – 925.
dc.identifier.citedreferenceNCI. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. NIH Publication # 09‐7473; 2009.
dc.identifier.citedreferenceBahrami A, Lee S, Wu G, et al. Pigment‐synthesizing melanocytic neoplasm with protein kinase C alpha (PRKCA) fusion. JAMA Dermatol. 2016; 152 ( 3 ): 318 – 322.
dc.identifier.citedreferenceHamm H, Hoger PH. Skin tumors in childhood. Dtsch Arztebl Int. 2011; 108 ( 20 ): 347 – 353.
dc.identifier.citedreferenceTrozak DJ, Rowland WD, Hu F. Metastatic malignant melanoma in prepubertal children. Pediatrics. 1975; 55 ( 2 ): 191 – 204.
dc.identifier.citedreferenceZembowicz A, Mihm MC. Dermal dendritic melanocytic proliferations: an update. Histopathology. 2004; 45 ( 5 ): 433 – 451.
dc.identifier.citedreferenceAntony FC, Sanclemente G, Shaikh H, Trelles AS, Calonje E. Pigment synthesizing melanoma (so‐called animal type melanoma): a clinicopathological study of 14 cases of a poorly known distinctive variant of melanoma. Histopathology. 2006; 48 ( 6 ): 754 – 762.
dc.identifier.citedreferenceVyas R, Keller JJ, Honda K, Cooper KD, Gerstenblith MR. A systematic review and meta‐analysis of animal‐type melanoma. J Am Acad Dermatol. 2015; 73 ( 6 ): 1031 – 1039.
dc.identifier.citedreferenceParsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331 ( 6016 ): 435 – 439.
dc.identifier.citedreferenceMorin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B‐cell lymphomas. Clin Cancer Res. 2016; 22 ( 9 ): 2290 – 2300.
dc.identifier.citedreferenceRobert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372 ( 4 ): 320 – 330.
dc.identifier.citedreferenceOtt PA, Hodi FS, Robert C. CTLA‐4 and PD‐1/PD‐L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013; 19 ( 19 ): 5300 – 5309.
dc.identifier.citedreferenceRobert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372 ( 26 ): 2521 – 2532.
dc.identifier.citedreferenceLarkin J, Chiarion‐Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373 ( 1 ): 23 – 34.
dc.identifier.citedreferenceMerchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high‐risk pediatric sarcomas. Clin Cancer Res. 2016; 22 ( 13 ): 3182 – 3191.
dc.identifier.citedreferenceChiou VL, Burotto M. Pseudoprogression and immune‐related response in solid tumors. J Clin Oncol. 2015; 33 ( 31 ): 3541 – 3543.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pbc26702.pdf
Size:
441.5KB
Format:
PDF
View/Open
Name:
pbc26702_am.pdf
Size:
510.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.